Skip to main content

Record Resources Completes Sale of Non-Core Assets at Lake Temiskaming as Company Prioritizes Gabon Oil Assets

CALGARY, Alberta, June 17, 2026 (GLOBE NEWSWIRE) — Record Resources Inc. (TSXV: REC) reports that it has sold the non-hydrocarbon and non-hydrogen rights on an optioned property at Lake Temiskaming, Ontario, reflecting the Company’s continued prioritization of its Gabonese oil and gas assets, focused on the Ngulu block, which covers 1,214 Km2 (equivalent to 54 Gulf of Mexico blocks) and is strategically located on trend to several sizable producing oil fields and includes the Loba oil field discovery and over 28 seismically identified high impact prospects in the Pre-salt Gamba / Dentale and Post-salt plays.  RJK Explorations (RJK), Kirkland Lake, Ontario, has acquired from Record Resources the rights to diamonds, precious and base metals found on the company’s Lorrain-Bucke property located at Lake Timiskaming, Ontario....

Continue reading

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs

Company to present at Planet Microcap Conference in Las Vegas between June 16-18 MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) — Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a biotechnology company developing a proprietary gel-based delivery platform for pharmaceutical, animal health and consumer health applications, today provided a corporate update on recent clinical and commercial milestones toward broader pharmaceutical adoption. Highlights Over the first half of 2026, Gelteq has commenced veterinary and pharmaceutical development programs, expanded its delivery platform, and advanced toward future clinical milestones including:Human clinical trial planning completed and the clinical trial is expected to commence next quarter (beginning July 1, 2026), which is anticipated to advance...

Continue reading

Foremost Clean Energy Receives Saskatchewan Exploration Incentive Funding to Advance Uranium Portfolio

VANCOUVER, British Columbia, June 17, 2026 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) is pleased to announce that it has received funding under the Government of Saskatchewan’s Targeted Mineral Exploration Incentive (“TMEI“) Program, further demonstrating provincial support for the Company’s uranium exploration activities in Saskatchewan. Foremost received a $50,000 grant based on eligible exploration expenditures incurred in the province, to support the continued advancement of the Company’s Saskatchewan uranium project portfolio in the prolific Athabasca Basin. The TMEI program is designed to encourage private sector investment in mineral exploration by providing eligible companies with funding for qualifying exploration expenditures. The...

Continue reading

Braiin Accelerates $20B+ Agentic AI Customer Experience as a Service (CXaaS) Market Expansion, Securing Landmark Australian Contract

MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) — Braiin Limited (NASDAQ: BRAI) today announces a landmark partnership with leading Australian enterprise BillCentral Pty Ltd, a leading Australian enterprise, to deploy Braiin’s pioneering full-stack Agentic AI-powered customer experience and call center platform across enterprise operations. The partnership represents a major milestone for Braiin’s expanding CXaaS (Customer Experience as a Service) division, and is expected to accelerate the commercial rollout of the company’s enterprise AI product suite across Australia and international markets. Natraj Balasubramanian, Chief Executive Officer of Braiin Limited, noted, “This partnership represents a significant validation point for Braiin’s Agentic AI strategy and our broader vision for the future of...

Continue reading

Ruanyun Edai Technology Unveils Smart Campus Services Business With Approximately US$9.49 Million in Cumulative Operating Revenue Since September 2025 Launch

Smart Campus Services generated approximately US$3.83 million in unaudited operating revenue during April and May 2026, underscoring accelerating momentum in the Company’s campus infrastructure platform strategy KUALA LUMPUR, Malaysia, June 17, 2026 (GLOBE NEWSWIRE) — Ruanyun Edai Technology Inc. (NASDAQ: RYET) (the “Company” or “Ruanyun”), an AI-driven education and technology company advancing its planned transformation into Formind Group, today unveiled its Smart Campus Services business to investors. Launched in September 2025, Smart Campus Services is a high-growth campus infrastructure business serving student-life, campus operations and institutional service needs. Based on unaudited management accounts, the Company’s Smart Campus Services business recorded approximately US$9.49 million (RMB65.54 million) in cumulative operating...

Continue reading

TOMI Advances Toward NSF Certification to Address Multi-Billion-Dollar Pharmaceutical, Biotech and Cleanroom Decontamination Markets

Certification process could position SteraMist® as a validated decontamination standard across biosafety cabinets, containment enclosures, cleanrooms, and life sciences facilities worldwide FREDERICK, Md., June 17, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced a major step toward achieving NSF certification for its patented SteraMist ionized Hydrogen Peroxide (iHP) technology, a milestone that could accelerate adoption across pharmaceutical manufacturing, biotechnology, cleanroom, biosafety, and laboratory markets worldwide. NSF International is a global, independent organization that develops public health standards and certifications to protect food, water, consumer products, and the environment. The initiative...

Continue reading

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant progress across manufacturing, regulatory and clinical development activities supporting ERNA-101, the Company’s lead oncology candidate. With manufacturing process development completed, GMP production underway, IND-enabling activities advancing and an Investigational New Drug (IND) submission planned for the third quarter of 2026, Ernexa believes it is well-positioned to initiate its first-in-human...

Continue reading

Duos Technologies Group Closes $55M Registered Direct Offering

JACKSONVILLE, Fla., June 17, 2026 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), a leading provider of adaptive, modular, and scalable Edge Data Center (“EDC”) solutions, today announced an underwritten registered direct offering of 2,000,000 shares of common stock and 3,800,000 pre-funded warrants at a price of $9.50 per share or warrant for total gross proceeds of approximately $55 million, before deducting underwriting discounts, commissions, and offering expenses. The registered direct offering was completed by a single large institutional investor, to support the Company’s continued growth plans. The net proceeds from the offering will be used to expand, accelerate, and further commercialize the Company’s Edge Data Center business and for working capital and general corporate...

Continue reading

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026 SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at Week 96 as a key secondary endpoint of the SOL-R trial SOL-R to remain masked through Week 96, with topline results now expected in 1Q 2028 New secondary endpoint addition to SOL-R has the potential to establish AXPAXLI as a best-in-disease agent for wet AMD and further differentiate potential label to support broad global adoption, if...

Continue reading

Mountain Crest Acquisition 6 Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing on June 22, 2026

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Mountain Crest Acquisition 6 Corp. (the “Company”) today announced that, commencing on June 22, 2026, holders of the 6,000,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”), may elect to separately trade the ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “MCAHU.” Any underlying ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “MCAH” and “MCAHR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, Continental Stock Transfer & Trust Company, in order to separate the holders’ Units into ordinary shares and rights. The Units were initially offered by the Company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.